A new study highlights the effectiveness and cost-effectiveness of Myriad™ in lower limb salvage surgery. From Investing.com

AUCKLAND, New Zealand, January 16, 2025 /PRNewswire/ — New Zealand The Aroa Biosurgery-based soft tissue regeneration company recently announced the release of further strong clinical evidence supporting both the efficacy and cost benefits of its AROA ECM™ technology when used in high-risk limb salvage surgery.

Conducted in between May 2022 and April 2023a single-site prospective clinical study included a total of 130 complex lower limb defects from 120 patients.

An astonishing 95% of patients included in the study had at least one risk factor for lower limb amputation, and 55% had 3 or more predictive risk factors for amputation.

Lower limb amputation can seriously impact quality of life, with a 5-year mortality rate for lower limb amputees as high as ~50%^[1].

Published in the December edition of the highly regarded peer-reviewed journal, Plastic and reconstructive surgery “Global Open, a real-world study called “Limb salvage by soft tissue surgical reconstruction with sheep foreskin matrix graft: a prospective study”, is the largest prospective study of its kind targeting in-hospital reconstruction of lower extremity defects with dermal matrices. The study is the first publication to emerge from the company’s ongoing prospective study, the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR).

The study found that AROA’s Myriad Matrix™ and Myriad Morcells™ achieved successful tissue coverage and filling in 30 days, after just one product application with no reported infections or complications.

With further validation of the use of Myriad products in these challenging lower extremity reconstructions^[2]study highlights the potential for significant cost benefits. The findings showed an estimated cost difference of up to 195%, compared to other commercially available dermal matrices, when used for in-hospital lower extremity reconstruction.

Founder and CEO of the company ASX-Listed company, Brian Ward says: “We are very pleased to see the first clinical evidence from our large prospective MASTRR study. The evidence from this study further supports both the efficacy and potential cost benefits associated with the use of Myriad in lower limb reconstruction procedures. With a total addressable market of 225 million USD^[3]only for procedures on the lower limbs, this represents a significant objectionluck for AROA.”

Head of the study, investigator dr. John Lawlor is an experienced foot and ankle surgeon based in Florida. “I have been using AROA’s Myriad products for several years and have seen the difference Myriad can make in my patient population. It is very encouraging to see this large study published, quantifying the significant positive impact on patients as well as the overall cost benefit associated with using Myriad for management this complex group of patients. I am excited to have the opportunity to share my data on positive outcomes with fellow surgeons,” he says Ph.D. Lawlor.

[1] Armstrong, DG, et al, Five-year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. Journal of Foot and Ankle Research2020. 13(1): p. 16.
[2] Bosque, BA, et al. Sheep foregut matrix in the surgical treatment of complex soft tissue defects of the lower extremities. magazine for American Podiatric Medical (TASE:) Association2023. 113(3).
[3] Assessments of the AROA administration